Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice
2008

Effects of Bupropion Metabolites on Seizures in Mice

Sample size: 120 publication Evidence: high

Author Information

Author(s): Peter H Silverstone, Robert Williams, Louis McMahon, Rosanna Fleming, Siobhan Fogarty

Hypothesis

The study investigates the convulsive liability and dose-response of bupropion metabolites in mice.

Conclusion

Bupropion metabolites increase the percentage of convulsing mice in a dose-dependent manner, with hydroxybupropion HCl being the most convulsive.

Supporting Evidence

  • Hydroxybupropion HCl treatment induced the largest percentage of convulsing mice (100% at both 50 and 75 mg/kg).
  • The percentage of convulsions differed between metabolites, with bupropion HCl showing the least convulsions.
  • Probit analysis revealed statistically significant differences in dose-response curves.

Takeaway

This study shows that some parts of a medicine called bupropion can make mice have seizures, especially when given in higher amounts.

Methodology

The study involved administering single doses of bupropion metabolites to female Swiss albino mice and observing for convulsions.

Limitations

The convulsive liability of the parent drug was not evaluated, and results may not translate to humans due to metabolic differences.

Participant Demographics

120 female Swiss Crl: CD1 (ICR) albino mice, approximately 7 weeks old.

Statistical Information

P-Value

p < 0.0001

Statistical Significance

p < 0.0001

Digital Object Identifier (DOI)

10.1186/1744-859X-7-19

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication